Background/Objectives: Autism spectrum disorder (ASD) lacks pharmacological therapies for its core features. This study synthesized chalcone derivatives, determined their monoamine oxidase A (MAO-A) and MAO-B inhibitory profiles, and generated computational hypotheses regarding MAO-B binding, gut–bacterial protein interactions, and drug-like properties. Methods: Sixteen chalcones (23–38; fifteen newly reported) were synthesized and characterized. MAO-A and MAO-B inhibition was measured using fluorometric concentration–response assays, with clorgyline and safinamide as references. Compounds 23, 26, 35, and 37 were docked against human MAO-B (PDB 2V5Z), Bacteroides fragilis profragilysin-3 (PDB 7POU), and Lacticaseibacillus casei thymidylate synthase (PDB 1LCA and 3IK1), and subjected to in silico ADMET assessment. Results: Compound 37 showed the best balance of MAO-B potency and selectivity, with an IC50 of 0.636 µM and a selectivity index of 16.65. Compound 35 was also MAO-B-selective (IC50 = 2.52 µM; selectivity index = 13.24). Compound 34 was the most potent dual inhibitor (MAO-A IC50 = 0.647 µM; MAO-B IC50 = 0.272 µM), whereas none met the predefined MAO-A-selectivity threshold. Docking suggested accommodation of the chalcones within the MAO-B cavity, the peripheral hesperetin-binding pocket of profragilysin-3, and the thymidylate-synthase folate/dUMP cleft. Predicted ADMET profiles indicated limited absorption, extensive protein binding, and potential hepatic and genotoxic liabilities. Conclusions: Compound 37 is the leading selective MAO-B scaffold, while compound 35 provides a second selective chemotype. The bacterial-target docking and ADMET findings are hypothesis-generating only and do not demonstrate effects on toxin activity, bacterial growth, microbiome composition, safety, central exposure, or ASD-related outcomes. Enzyme kinetics, target-engagement, permeability, genotoxicity, and microbiological studies are required before in vivo evaluation.